Clinical Trials and Market Position - As of June 30, 2023, Cryoport supported 668 clinical trials, including 82 in Phase 3, and twelve commercial therapies, indicating a strong position in the clinical trial and commercial launch market for cell and gene therapies [105]. - The biopharma/pharma market raised over $12 billion in funding for cell and gene therapies in 2022, with 1,457 developers worldwide, highlighting significant growth opportunities for Cryoport's supply chain solutions [110]. - The number of clinical trials supported increased to 668, with 82 Phase 3 trials as of June 30, 2023 [122]. - The company aims to support the life sciences industry by providing innovative temperature-controlled supply chain solutions, which are critical for the distribution of high-value biologic products [104]. Financial Performance - Total revenues decreased by $7.1 million, or 11.1%, from $64.2 million in Q2 2022 to $57.0 million in Q2 2023 [119]. - Total revenues increased by $3.4 million, or 2.9%, from $116.5 million in 2022 to $119.8 million in 2023, driven by recovery from the New Prague Fire [136]. - Service revenues increased by $0.6 million, or 1.8%, from $34.6 million to $35.2 million, driven by a 38% increase in bioservices revenue [120]. - Service revenues rose by $3.5 million, or 5.3%, from $67.5 million to $71.0 million, attributed to increased demand for supply chain solutions [137]. - Product revenues decreased by $7.8 million, or 26.2%, from $29.6 million to $21.8 million, primarily due to a 67% decline in demand for cryogenic systems in China [121]. - Product revenues decreased by 0.3%, from $49.0 million to $48.8 million, primarily from cryogenic stainless-steel freezers and related equipment [138]. - Gross margin for total revenues was 43.4% in Q2 2023, down from 45.0% in Q2 2022 [125]. - Gross margin for total revenues was 43.2% in 2023, down from 43.9% in 2022, with total cost of revenues increasing by $2.8 million to $68.0 million [142]. - Selling, general and administrative expenses increased by $8.2 million, or 27.0%, due to scaling operations and integration costs [129]. - Selling, general and administrative expenses increased by $14.9 million, or 26.0%, driven by scaling operations and integration costs [146]. - Engineering and development expenses rose by $0.7 million, or 21.1%, focusing on enhancing logistics and supply chain solutions [130]. - Engineering and development expenses rose by $1.1 million, or 15.3%, focused on enhancing logistics and supply chain solutions [148]. - Investment income increased by $0.6 million due to higher average invested cash balances and interest rates [131]. - Investment income increased by $1.8 million due to higher average invested cash balances and interest rates [149]. - Other income increased by $3.3 million, primarily from short-term investment net gains and foreign currency fluctuations [132]. - Other income (expense), net improved by $12.3 million, primarily from short-term investment gains and an insurance claim related to the New Prague fire [150]. - The provision for income taxes increased by $0.4 million, resulting in effective tax rates of negative 4.9% in 2023 compared to negative 3.2% in 2022 [151]. - Adjusted EBITDA for the six months ended June 30, 2023, was a loss of $1.4 million, compared to a gain of $8.0 million in the same period in 2022 [157]. Operational Challenges and Strategic Developments - The ongoing conflict in Ukraine and associated sanctions have created uncertainties that could impact Cryoport's business operations and financial performance, particularly in Europe [117]. - Cryoport has experienced supply chain disruptions due to COVID-19, impacting material sourcing and transportation costs, which may affect future operations [113]. - The company signed a three-year agreement with Boston IVF to integrate its supply chain solutions across the U.S. [124]. - The company recognized that it may need additional capital to fund operations and potential acquisitions until sustained profitable operations are achieved [164]. Cash Flow and Investments - As of June 30, 2023, the company had cash and cash equivalents of $67.3 million and short-term investments of $437.4 million, with total working capital of $544.9 million [163]. - The company reported a net cash used in operating activities of $(1.3 million) for the six months ended June 30, 2023, compared to $(6.487 million) for the same period in 2022, indicating an improvement of $5.207 million [165]. - Net cash provided by investing activities was $32.3 million for the six months ended June 30, 2023, primarily due to the maturity of short-term investments of $52.5 million [167]. - The estimated fair value of the Convertible Senior Notes as of June 30, 2023, was $320.7 million [172]. - The company has a repurchase program authorized for up to $100 million, with no shares repurchased during the six months ended June 30, 2023 [169]. - Based on foreign-denominated cash balances as of June 30, 2023, a 5%, 10%, and 20% adverse change in foreign exchange would result in declines of $1.3 million, $2.6 million, and $5.2 million, respectively [174]. Future Outlook - The company anticipates that regenerative medicine therapies will become significant revenue drivers as they advance through clinical trials and receive regulatory approvals [105]. - Revenues from the international business accounted for 39% of consolidated revenues, decreasing by $0.2 million compared to the same period in the prior year due to foreign exchange fluctuations [173].

Cryoport, Inc. (NASDAQ:CYRX) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Todd Fromer - Investor Relations Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Puneet Souda - SVB Securities Matthew Stanton - Jefferies John Sourbeer - UBS David Larsen - BTIG Paul Knight - KeyBanc Capital David Saxon ...

Financial Performance - Total revenues increased by $10.5 million, or 20.1%, from $52.3 million in Q1 2022 to $62.8 million in Q1 2023, driven by recovery from the New Prague Fire and strong demand for supply chain solutions [230]. - Service revenues rose by $2.9 million, or 8.9%, from $32.9 million to $35.8 million, attributed to strong customer demand for Cryoport's supply chain solutions [231]. - Product revenues surged by $7.6 million, or 39.1%, from $19.4 million to $27.0 million, primarily due to recovery from the New Prague Fire [232]. - Revenue from the biopharma/pharma market increased by $8.1 million, or 18.9%, from $43.0 million to $51.1 million, supported by global clinical trials and demand for logistics services [233]. - Gross margin for total revenues improved to 43.1% in Q1 2023 from 42.7% in Q1 2022, with total cost of revenues rising by $5.8 million to $35.7 million [236]. - Net loss attributable to common stockholders decreased by $7.8 million, or 50.8%, from $15.4 million to $7.6 million [240]. - For the three months ended March 31, 2023, the GAAP net loss was $5.6 million, a significant improvement from a net loss of $13.4 million in the same period of 2022 [252]. - Adjusted EBITDA for the same period was $2.9 million, compared to $2.0 million in the prior year, indicating a year-over-year increase of approximately 46.4% [252]. - Revenues reported for the three months ended March 31, 2023, totaled $62.8 million, with a non-GAAP constant currency revenue of $64.3 million, reflecting a decrease of $1.4 million due to foreign exchange impacts [259]. Operational Highlights - As of March 31, 2023, Cryoport supported 652 clinical trials, including 82 in Phase 3 and 10 commercial therapies [215]. - Cryoport's advanced temperature-controlled supply chain solutions are critical for the distribution of high-value biologic and cell-based products regulated by the FDA and EMA [214]. - The company operates 48 strategic international locations, serving over 3,000 customers in the life sciences industry [213]. - Cryoport's mission is to provide certainty throughout the temperature-controlled supply chain, supporting life sciences to save and improve lives globally [217]. - The company is focused on supporting the animal health market and human reproductive market, particularly through IVF technologies [216]. - Cryoport's solutions are designed to address supply chain challenges faced by cell and gene therapy developers, enhancing their operational efficiency [219]. Insurance and Incident Impact - The New Prague fire in January 2022 resulted in an estimated revenue impact of approximately $9.4 million, primarily in Q1 2022 [225]. - Cryoport received a total of $15.1 million in insurance proceeds related to the New Prague fire, with the final payment of $2.2 million received in Q1 2023 [226]. - Other income (expense), net improved by $9.0 million, primarily due to a gain on an insurance claim related to the New Prague fire [244]. Market and Economic Conditions - The biopharma/pharma market raised over $12 billion in funding for cell and gene therapies in 2022, with 1,457 developers worldwide [219]. - The ongoing conflict in Ukraine may lead to significant volatility in commodity prices and supply chain disruptions, impacting Cryoport's operations [228]. Expenses and Cash Flow - Selling, general and administrative expenses increased by $6.6 million, or 24.9%, to $33.2 million, driven by scaling operations and increased employee costs [241]. - Engineering and development expenses rose by $0.3 million, or 9.5%, to $3.9 million, focusing on enhancing Cryoport Express® Solutions and related technologies [242]. - Investment income increased by $1.2 million, or 95.2%, due to higher average invested cash balances and interest rates [243]. - The company had cash and cash equivalents of $38.5 million and short-term investments of $484.1 million as of March 31, 2023, with total working capital of $563.1 million [260]. - Operating activities generated cash of $2.8 million, while investing activities used $1.4 million, resulting in a net increase in cash and cash equivalents of $1.9 million for the quarter [262]. - The company expects to continue incurring operating losses in the near term while investing in new supply chain initiatives and geographic expansion [260]. Shareholder and Capital Management - The company has a repurchase program authorized for up to $100 million, with no shares repurchased during the three months ended March 31, 2023 [266]. - The company recognizes the need for additional capital to fund operations and potential acquisitions until sustained profitable operations are achieved [261]. - As of March 31, 2023, the estimated fair value of the Convertible Senior Notes was $316.4 million [269].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 (State or other juris ...

Cryoport, Inc. (NASDAQ:CYRX) Q4 2022 Earnings Conference Call February 23, 2023 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Mark Sawicki - Chief Scientific Officer Conference Call Participants Michael Almisry - SVB Securities Matt Stanton - Jefferies John Sourbeer - UBS David Larsen - BTIG David Saxon - Needham & Company Jacob Johnson - Stephens Yuan Zhi - B. Riley Securities Operator Good afternoo ...

Cryoport, Inc. (NASDAQ:CYRX) Q3 2022 Results Conference Call November 3, 2022 5:00 PM ET Company Participants Todd Fromer - Managing Partner-KCSA Jerrell Shelton - Chief Executive Officer Robert Stefanovich - Chief Financial Officer Dr. Mark Sawicki - Chief Scientific Officer Thomas Heinzen - Vice President, Corporate Development and Investor Relations Conference Call Participants Puneet Souda - SVB Securities John Sourbeer - UBS Brandon Couillard - Jefferies David Larsen - BTIG David Saxon - Needham & Comp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313 ...

Cryoport, Inc. (NASDAQ:CYRX) Q2 2022 Earnings Conference Call August 4, 2022 5:00 PM ET Company Participants Todd Fromer – Managing Partner-KCSA Jerrell Shelton – Chief Executive Officer Tom Heinzen – Vice President, Corporate Development and Investor Relations Robert Stefanovich – Chief Financial Officer Mark Sawicki – Chief Scientific Officer Conference Call Participants John Sourbeer – UBS Richard Baldry – Roth Capital Yuan Zhi – B. Riley Securities David Saxon – Needham & Co. David Larsen – BTIG Jacob J ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-34632 CRYOPORT, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 88-0313393 ( ...

CRYOPORT, INC. (NASDAQ: CYRX) FIRST QUARTER 2022 IN REVIEW May 5, 2022 Important information This document provides a review of Cryoport, Inc.'s recent financial and operational performance and a general business outlook. It is designed to be read by interested parties before the regularly scheduled quarterly conference call, which, for this quarter, is scheduled for 5:00 p.m. ET on Thursday, May 5, 2022. Therefore, the conference call will be in the format of a questions and answers session and will addres ...